Navigation Links
New Poll: Voters Want to Reduce Wasteful Spending in Medicaid Pharmacy
Date:12/10/2010

icaid costs acceptable when they involve reducing costs for prescription drugs, but find cutting payments to physicians and hospitals unacceptable.  Voters find "requir[ing] Medicaid patients to use generic drugs unless their doctor objects" acceptable by an 85 to 12 percent margin, find "mak[ing] local drugstores compete with each other in order to be included in a Medicaid network, like they do for Medicare Part D and private sector plans" acceptable by a 74 to 16 percent margin, and find "mak[ing] sure that different pharmacies do not issue duplicate prescriptions to the same patient" acceptable by a 74 to 20 percent margin.
  • Voters find cutting payments to physicians and hospitals who see Medicaid payments unacceptable by 64 to 29 percent and 61 to 31 percent margins, respectively.
  • One likely reason for voters' flexibility regarding Medicaid pharmacy is that the vast majority of voters have at least three pharmacies in their area.  Eighty-five percent of voters have at least three pharmacies in their area, including 61 percent who have more than five pharmacies in their area.

  • Key Findings from The Lewin Group study:

    Savings Opportunities Exist In Four Key Areas

    While Medicaid FFS programs and costs vary greatly state-by-state, The Lewin Group identified four key areas where pharmacy benefit management could generally be improved:

    • Generic Drug Dispensing: Medicaid FFS is less effective at encouraging the dispensing of generic drugs in place of brands. The generic dispensing rate in Medicaid FFS averages 68%, compared to an average 80% generic dispensing rate in Medicaid MCOs.
    • Dispensing Fees: At $4.81 per prescription, the national average dispensing fee that Medicaid FFS programs pay to retail pharmacies per each prescription is more than double the average dispensing fees paid by Medicare Part D p
      '/>"/>

    SOURCE Pharmaceutical Care Management Association
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Consumer Reports Flu Poll: Approximately Three Out of 10 Health Care Workers Living in a Bubble, Not Getting Flu Vaccine
    2. Mindset Media Study Reveals Which Independent Voters Favor Obama Vs. McCain
    3. CareFusion Launches Respiratory Airway Adapter to Improve Patient Safety and Reduce Hospital Costs
    4. Passages Malibu Drug and Alcohol Treatment Center Announces Launch of Cutting-Edge Brain Paint Neurofeedback Therapy Scientifically Proven to Reduce Addiction Relapse Rate Into Pioneering Holistic Treatment Program
    5. Radiology Journal Publishes Data That PEM Scanners May Reduce Unnecessary Breast Biopsies and Offer an Alternative for Women Who Cannot Tolerate MRI
    6. Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows
    7. Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP
    8. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
    9. In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function
    10. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
    11. New Deloitte Recap Report Identifies Strategies to Help Reduce Development Times and Increase Success Rates for Cancer Drugs
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... to 2020 - Broadened Diagnostic Criteria ... Market Growth despite Patent Expirations ... ADHD Therapeutics to 2020 - ...
    (Date:8/28/2014)... 28, 2014 Amgen (NASDAQ: AMGN ... Application (BLA) to the U.S. Food and Drug Administration ... high cholesterol. Evolocumab is an investigational fully human monoclonal ... a protein that reduces the liver,s ability to remove ... blood. 1 ­ The ...
    (Date:8/28/2014)... , Aug. 28, 2014  Rx Safes, Inc., ... announced that it is waging a new war on ... national media campaign. More than 2,500 children ... time and these drugs are easily accessed from unsecured medicine ... drug dealers on the streets, Rx Safes will address ...
    Breaking Medicine Technology:ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9Rx Safes, Inc. Announces New War On Drugs 2
    ... , SAN DIEGO, Sept. 9 Anadys Pharmaceuticals, Inc. ... in a Phase II trial of ANA598 in patients chronically infected ... over 12 weeks, taken in combination with pegylated interferon-alpha and ribavirin, ... non-nucleoside polymerase inhibitor. , , "ANA598 has demonstrated ...
    ... , , HERNDON, Va., Sept. 8 ... that it will initiate a global, Phase 3, multi-center pivotal trial ... proprietary BHR-100 intravenous progesterone infusion product as a neuroprotective agent for ... , BHR will enroll approximately 1,200 patients with ...
    Cached Medicine Technology:Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598 2Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598 3Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598 4Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598 5BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury 2
    (Date:8/28/2014)... 28, 2014 ABC television stars will ... MDA Show of Strength Telethon airing Sunday, Aug. 31, ... help raise funds and awareness to help save and ... muscle disease. , Viewers tuning into the 2014 telethon ... appeals and introductions from some of the network’s leading ...
    (Date:8/28/2014)... 28, 2014 Biotronic, a Great Point ... neurophysiology monitoring ("IONM") company, today announced the promotion of ... Chief Executive Officer effective immediately. Mr. Gecsey joined Biotronic ... CFO in 2013 and has been an integral part ... efforts and achievements since joining the company in 2010 ...
    (Date:8/28/2014)... 2014 Allegheny Health Network ... regional partnership designed to advance sports nutrition education, ... young athletes, scholastic athletes and their families across ... & Mind Initiative will offer a comprehensive and ... and mental dynamics involved in pursuing athletic excellence,” ...
    (Date:8/28/2014)... 28, 2014 Valero Renewable Fuels Company, ... (NYSE: VLO), and the Ports of Indiana hosted Lt. ... today at a Port Appreciation and Welcome Celebration commemorating ... plant. , “The opening of Valero’s ethanol facility at ... economic development win for the State of Indiana,” Ellspermann ...
    (Date:8/28/2014)... (PRWEB) August 28, 2014 Gurnick Academy ... MRI Technology program is re-accredited for the 5 years ... Resonance Imaging Technologists (ARMRIT). , “We are very ... constantly improving our program to make sure we provide ... lot of interest in MRI field nowadays and I ...
    Breaking Medicine News(10 mins):Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2
    ... a blood vessel medication, improved distances 50% ... prescription drug naftidrofuryl eases leg cramps caused by ... farther, according to Belgian researchers. , They reviewed ... condition called intermittent claudication. Patients who took the ...
    ... Brain function and health will be the focus of the ... in San Francisco. Part of a highly recognized series, ... with the booming aging industry; factors that predict future cognitive ... participate in them. , WHO: , The program is sponsored ...
    ... On Sunday, June 29,2008, West Coast Bank will sponsor ... Run, Portland,s most unique 8k personal,challenge run., Race ... the,Burnside Bridge by 9:00 a.m. when the bridge rises. ... the Oregon Zoo and winds through the,paved roads of ...
    ... are estimated to be affected by the devastation caused ... by researchers from the Johns Hopkins Bloomberg School of ... Systems (GIS), the researchers calculated the likely distribution of ... developed maps of the regions at greatest risk from ...
    ... and Vancouver Coastal Health Research Institute have discovered how ... body and are working toward a treatment to block ... discovery, published today in the journal Cell Host and ... and its newly discovered counterpart protein in the human ...
    ... broader public action to curb effects , , WEDNESDAY, May 14 ... particulate matter air pollution can increase blood pressure and harm ... , The findings may explain why air pollution can trigger ... failure and stroke, the researchers said. , Particulate matter (PM) ...
    Cached Medicine News:Health News:Common Drug Eases Leg Pain From Walking 2Health News:Estimated 3.2 million Burmese potentially affected by cyclone 2Health News:Vancouver researchers discover missing link between TB bacteria and humans 2Health News:Pollution Particles Impair Blood Vessel Function 2
    96 channel Parallel dispenser using Positive Air Displacement Technology...
    The WellPro 384 is designed for use with 384 well microplates. It utilizes a 24 channel liquid head and can perform serial dilutions in a 16 or 24 across format, and plate to plate transfers and plat...
    The WP1000S is a shortened base version of the WellPro that is shortened 5 inches to facilitate fitting into smaller biohazard hoods....
    ... The Labcyte Echo 550 compound ... droplets down to 5 nL using ... on focused acoustic energy. Monitoring of ... fluids enables the Echo 550 to ...
    Medicine Products: